Practical Viewpoints on the Diagnosis and Management of Heparin-Induced Thrombocytopenia

ABSTRACT

Heparin-induced thrombocytopenia (HIT, type II) is an immune-mediated disorder due to antibodies formed against heparin–platelet factor 4 complexes, usually appearing at days 5 to 14 after initiation of heparin. It is important to recognize HIT because heparin prophylaxis or treatment paradoxically associates with new venous and/or arterial thrombosis. Early clinical suspicion and diagnosis together with proper pharmacotherapy and close laboratory monitoring are the cornerstones for successful management. This includes monitoring of Thrombocytopenia, its Timing to heparin administration, appearance of new Thrombosis or resistance to treatment, and differential diagnosis by exclusion of oTher causes (the 4T's). Specific attention should be paid to the absence or presence of thrombosis and to tailoring thromboprophylaxis or anticoagulant therapy with a nonheparin alternative. Even in the absence of HIT-associated thrombosis, an active policy for prolonged thromboprophylaxis is demanded. Rapid and reliable assays should be developed for diagnosis and anticoagulation monitoring to secure safe management with nonheparins. Semiquantitative testing for on-call hours should be available and later confirmed as clinically needed. Alternative therapeutic options are available, but because their use is infrequent, experienced coagulation treatment centers should provide guidance in the treatment and in laboratory monitoring. Most of the evidence in HIT is grade IC, and thus the best evidence is provided by clinical experience. New anticoagulants and platelet inhibitors may offer future alternatives in the management of HIT, but the current treatment options provide the best experience and benefit. The joint clinical and laboratory guidelines provided in this article along with two practical case scenarios were prepared by a Nordic expert panel. They will be valuable for hematologists and colleagues who do not routinely encounter HIT.

Heparin-induced thrombocytopenia - HIT - platelet count - thrombosis - thromboprophylaxis

REFERENCES

• 1 Martel N, Lee J, Wells P S. Risk for heparin-induced thrombocytopenia with unfractionated and low molecular weight heparin thromboprophylaxis.  Blood. 2005;  106 2710-2715
• 2 Kuitunen A, Raivio P, Suojaranta-Ylinen R, Kukkonen S, Lassila R. Heparin-induced thrombocytopenia following cardiac surgery is associated with poor outcome.  J Cardiothorac Vasc Anesth. 2007;  21 18-22
• 3 Tschudi M, Lämmle B, Alberio L. Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients.  Blood. 2009;  113 2402-2409
• 4 Salmela B, Joutsi-Korhonen L, Saarela E, Lassila R. Monitoring of direct thrombin inhibitor lepirudin.  Thromb Res. 2010;  125 538-544
• 5 Warkentin T E, Greinacher A, Koster A, Lincoff A M. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians Evidence Based Clinical Practice Guidelines (8th edition).  Chest. 2008;  133 340-380
• 6 Magnani H N, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.  Thromb Haemost. 2006;  95 967-981
• 7 Lo G K, Juhl D, Warkentin T E, Sigouin C S, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings.  J Thromb Haemost. 2006;  4 759-765
• 8 Arepally G M, Ortel T L. Clinical practice. Heparin-induced thrombocytopenia.  N Engl J Med. 2006;  355 809-817
• 9 de Maistre E, Gruel Y, Lasne D. Diagnosis and management of heparin-induced thrombocytopenia.  Can J Anaesth. 2006;  53 (6, Suppl) S123-S134
• 10 Greinacher A, Ittermann T, Bagemuehl J et al.. Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests.  J Thromb Haemost. 2010;  8 2025-2031
• 11 Eichler P, Raschke R, Lubenow N, Meyer O, Schwind P, Greinacher A. The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays.  Br J Haematol. 2002;  116 887-891
• 12 Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review.  Semin Thromb Hemost. 2006;  32 803-809
• 13 Pouplard C, Gueret P, Fouassier M et al.. Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia.  J Thromb Haemost. 2007;  5 1373-1379
• 14 Warkentin T E, Sheppard J I, Moore J C, Sigouin C S, Kelton J G. The quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays.  J Thromb Haemost. 2008;  6 1304-1312
• 15 Warkentin T E. Heparin-induced thrombocytopenia: pathogenesis and management.  Br J Haematol. 2003;  121 535-555
• 16 Zwicker J I, Uhl L, Huang W Y, Shaz B H, Bauer K A. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia.  J Thromb Haemost. 2004;  2 2133-2137